Novel method of treating macular degeneration: a patent evaluation (WO2018/107005)

References

• The Lancet. Age-related macular degeneration: treatment at what cost? Lancet. 2018;392:1090.
   Web of Science ®Google Scholar
• Mitchell P, Liew G, Gopinath B, et al. Age-related macular degeneration. Lancet. 2018;392:1147–1159.
   PubMed Web of Science ®Google Scholar
• Al-Zamil WM, Yassin SA. Recent developments in age-related macular degeneration: a review. Clin Interv Aging. 2017;12:1313–1330.
   PubMed Web of Science ®Google Scholar
• Hernandez-Zimbron LF, Zamora-Alvarado R, Ochoa-De la Paz L, et al. Age-related macular degeneration: new paradigms for treatment and management of AMD. Oxid Med Cell Longev. 2018;2018:8374647.
   PubMed Web of Science ®Google Scholar
• Abd AJ, Kanwar RK, Kanwar JR. Aged macular degeneration: current therapeutics for management and promising new drug candidates. Drug Discov Today. 2017;22:1671–1679.
   PubMed Web of Science ®Google Scholar
• Li H, Chintalapudi SR, Jablonski MM. Current drug and molecular therapies for the treatment of atrophic age-related macular degeneration: phase i to phase iii clinical development. Expert Opin Investig Drugs. 2017;26:1103–1114.
   PubMed Web of Science ®Google Scholar
• Yonekawa Y, Miller JW, Kim IK. Age-related macular degeneration: advances in management and diagnosis. J Clin Med. 2015;4:343–359.
   PubMed Web of Science ®Google Scholar
• Mehat MS, Sundaram V, Ripamonti C, et al. Transplantation of human embryonic stem cell-derived retinal pigment epithelial cells in macular degeneration. Ophthalmology. 2018;125:1765–1775.
   PubMed Web of Science ®Google Scholar
• Takahashi M. [Retinal cell therapy using IPS cells]. Nippon Ganka Gakkai Zasshi. 2016;120: 210–224. discussion 25.
   PubMedGoogle Scholar
• Waugh N, Loveman E, Colquitt J, et al. Treatments for dry age-related macular degeneration and stargardt disease: a systematic review. Health Technol Assess. 2018;22:1–168.
   PubMed Web of Science ®Google Scholar
• Su Y, Wu J, Gu Y. Photodynamic therapy in combination with ranibizumab versus ranibizumab monotherapy for wet age-related macular degeneration: a systematic review and meta-analysis. Photodiagnosis Photodyn Ther. 2018;22:263–273.
   PubMed Web of Science ®Google Scholar
• Zhang X, Lai TYY. Baseline predictors of visual acuity outcome in patients with wet age-related macular degeneration. Biomed Res Int. 2018;2018:9640131.
   PubMedGoogle Scholar
• Hernandez-Zimbron LF, Zamora-Alvarado R. Ochoa-De la Paz L, et al. Age-related macular degeneration: new paradigms for treatment and management of AMD. Oxid Med Cell Longevity. 2018;2018:8374647.
   PubMed Web of Science ®Google Scholar
• Askou AL, Alsing S, Holmgaard A, et al. Dissecting microrna dysregulation in age-related macular degeneration: new targets for eye gene therapy. Acta Ophthalmol. 2018;96:9–23.
   PubMed Web of Science ®Google Scholar
• Becerra EM, Morescalchi F, Gandolfo F, et al. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration. Curr Drug Targets. 2011 Feb;12(2):149–172.
   PubMed Web of Science ®Google Scholar
• Ehrenberg M, Benny O. Evolving multidimensional pharmacological approaches to CNV therapy in AMD. Curr Eye Res. 2018;43:147–154.
   PubMed Web of Science ®Google Scholar
• Gil-Martínez M, Santos-Ramos P, Fernández-Rodríguez M, et al. Pharmacological advances in the treatment of age-related macular degeneration. Curr Med Chem. Frothcoming 2019. DOI:10.2174/0929867326666190726121711.
   PubMedGoogle Scholar
• Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292–2299.
   PubMed Web of Science ®Google Scholar
• Vo TA, Abedi S, Schneider K, et al. Effects of bevacizumab, ranibizumab, and aflibercept on phagocytic properties in human RPE cybrids with amd versus normal mitochondria. Exp Eye Res. 2018;177:112–116.
   PubMed Web of Science ®Google Scholar
• Ehlken C, Helms M, Bohringer D, et al. Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol. 2018;12:13–20.
   PubMed Web of Science ®Google Scholar
• Ehlken C, Bohringer D, Agostini HT, et al. Potential selection bias in candidates for stereotactic radiotherapy for neovascular amd. Graefes Arch Clin Exp Ophthalmol. 2018;256:105–111.
   PubMed Web of Science ®Google Scholar
• Cai S, Yang Q, Li X, et al. The efficacy and safety of aflibercept and conbercept in diabetic macular edema. Drug Des Devel Ther. 2018;12:3471–3483.
   PubMed Web of Science ®Google Scholar
• Sangroongruangsri S, Ratanapakorn T, Wu O, et al. Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis. Expert Rev Clin Pharmacol. 2018;11:903–916.
   PubMed Web of Science ®Google Scholar
• Van Asten F, Michels CTJ, Hoyng CB, et al. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration – a cost-effectiveness analysis from a societal perspective. PLoS One. 2018;13:e0197670.
   PubMed Web of Science ®Google Scholar
• Mohamed R, Saunders DC, Mathews JP. Consulting the consultants: avastin in the treatment of wet AMD. Eye (Lond). 2019;33:529–531.
   PubMed Web of Science ®Google Scholar
• Cohen D. Bayer and Novartis appeal ruling that avastin for wet AMD is lawful. BMJ. 2018;363:k4586.
   PubMedGoogle Scholar
• Cohen D. CCGS win right to offer patients avastin for wet AMD. BMJ. 2018;362:k4035.
   PubMedGoogle Scholar
• Smith AG, Kaiser PK. Emerging treatments for wet age-related macular degeneration. Expert Opin Emerg Drugs. 2014;19:157–164.
   PubMed Web of Science ®Google Scholar
• Ranibizumab and retinal vein occlusion. Too many outstanding questions. Prescrire Int. 2012;21:207.
   PubMedGoogle Scholar
• Borodic GE. Novel method of treating macular degeneration. 2018;WO2018107005:A1.
   Google Scholar
• Mastrolorenzo A, Supuran CT. Botulinum toxin, tetanus toxin and anthrax lethal factor inhibitors. In: Supuran CT, Winum JY, editors. Drug design of zinc-enzyme inhibitors: functional, structural, and disease applications. Hoboken: Wiley; 2009. p. 705–720.
   Google Scholar
• Jabbari B. History of botulinum toxin treatment in movement disorders. Tremor Other Hyperkinet Mov (N Y). 2016;6:394.
   PubMed Web of Science ®Google Scholar